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 The development of carbapenem gives a revolutionary 
impact to the chemotherapy of infectious diseases. The bac-
teriological and clinical efficacies of carbapenems, including 
imipenem/cilastatin, panipenem/betamipron, meropenem and 
biapenem, were evaluated. All four carbapenems were potent 
against gram-positive and gram-negative bacteria except 
Stenotrophomonas maltophilia. The antimicrobial activities of 
meropenem against Enterobacteriaceae were slightly superior 
to other carbapenems. Imipenem and panipenem were slightly 
more active against gram-positive bacteria than meropenem and 
biapenem. Biapenem was the most potent against Acinetobacter 
anitratus. The in vitro activity of imipenem was compared 
between 1990 and 1992 in Nagasaki University Hospital. 
The resistance rate of S. aureus, whose MIC is higher than 25 
mg/l, increased from 3% to 22%, S. pneumoniae, whose MIC 
is higher than 0.05 mg/l, increased from 9% to 30% and P. 
aeruginosa, whose MIC is higher than 5 mg/l, increased from 
20% to 32%. The isolation rates of S. maltophilia from sputum 
increased gradually from 0.9% in 1984 to 3.5% in 1991. 
 The clinical efficacy rates of imipenem/cilastatin and 
panipenem/betamipron were 79% and 77%, and the rates of 
meropenem and biapenem 100% and 96.2% for the treatment 
of respiratory infection in our department, respectively. The 
efficacy rates of imipenem/cilastatin decreased from 79% 
to 67.7% after being commercialized. This decline was due 
to administration to patients with severe underlying diseases 
and with infection caused by resistant strains such as P. 
aeruginosa and S. aureus. 
 The phase II and III trials of carbapenems in internal 
medicine, which were performed separately in Japan, showed 
that the clinical efficacy rates were 73%, 79%, 86% and 
89%, and the rates of adverse reaction were 4.7%, 3.3%, 1.8% 
and 2.2% in imipenem /cilastatin, panipenem / betamipron, 
meropenem and biapenem, respectively. Newly developed
carbapenems such as biapenem improved the clinical efficacy 
although the difference of clinical efficacies between imipe 
nem/cilastatin and other carbapenems was not statistically 
significant in double-blind comparative studies.
Introduction 
 Carbapenem compounds are bactericidal and potent 
antimicrobial agents with broad spectra against gram-
positive and gram-negative bacteria, and more stable 
against beta-lactamase than cephems. Imipenem/cilastatin 
has been on commercial preparation in Japan since 1987, 
followed by panipenem/betamipron in 1993. Meropenem 
and biapenem have been developed with a great ex-
pectancy to be more potent without dehydropeptidase 
inhibitor than other carbapenems. 
 The development of carbapenem gives a revolutionary 
impact to the chemotherapy of infectious diseases, espe-
cially severe infection. However, physicians have noticed 
increase in refractory infection even with carbapenem 
treatment. We have studied the in vitro activities of 4 
carbapenems and evaluated their clinical effects by 
reviewing phase II and III trials of carbapenems in 
Japan, including our own experience.
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1. Materials and Methods 
1.1 In vitro activity of 4 carbapenems against clinical isolates 
 In vitro susceptibility test was conducted on 27-33 
strains of 15 species (270 organisms) isolated from 
patients in Nagasaki University Hospital in 1993. The 
micro-broth 2-fold dilution method using the MIC 2000 
system (Dynatech Co.) was used to determine the 
minimum inhibitory concentration (MIC) of each drug. 
Imipenem, panipenem, meropenem, and biapenem were 
kindly offered from Banyu, Sankyo, Sumitomo, and
Lederle Japan, respectively. 
1.2 The change of susceptibility of clinical isolates to imipenem 
 The susceptibility of 12 species of clinical isolates in 
Nagasaki University Hospital to Imipenem was compared 
between 2640 isolates in 1990 and 3037 isolates in 1992 
using the microbroth dilution method mentioned above. 
 The isolation rates of S. maltophilia from sputum were 
observed in patients in Nagasaki University Hospital 
from 1984 to 1991.
1.3 The clinical evaluation of 4 carbapenems reviewing 
      from phase II and III trials performed in Japan 
 The phase II and III trials of imipenem /cilastatin, 
panipenem/betamipron, meropenem and biapenem were 
performed independently in Japan (Table 3). / Imipenem 
/cilastatin was administered to 529 patients including 
419 respiratory infection, 46 urinary tract infection, 35 
sepsis, 11 abdominal infection and 18 other infection from 
1980 to 1982. Panipenem/betamipron was administered 
to 446 patients including 396 respiratory infection, 23 
urinary tract infection, 19 seps is, 2 abdominal infection 
and 6 other infection from 1988 to 1990. Meropenem 
was administered to 567 patients including 532 respiratory 
infection, 17 urinary tract infection, 6 sepsis, 6 abdominal 
infection and 6 other infection from 1989 to 1991.
Biapenem was administered to 511 patients including 
485 respiratory infection, 11 urinary tract infection, 9 
sepsis, 5 abdominal infection and 1 other infection 
from 1991 to 1993. We reviewed their clinical records 
and individual data were analyzed with kind permis-
sion of each pharmaceutical companies.
2. Results 
2.1. In vitro activity of 4 carbapenems against clinical isolates 
  All four carbapenems were potent against gram-positive 
and gram-negative bacteria except Stenotrophomonas 
maltophilia (Table 1). Their antimicrobial activities were 
similar against most organisms, however, the antimicrobial 
activities of meropenem against Escherichia coli, Klebsiella 
pneumoniae, Proteus vulgaris, Citrobacter freundii, Enterobacter 
cloacae, Pseudomonas aeruginosa, and Hemophilus influenzae 
were superior to those of imipenem, panipenem and 
biapenem. Imipenem and panipenem were slightly more 
active against methicillin sensitive-Staphylococcus aureus 
(MSSA), S. epidermidis and E. faecalis than meropenem 
and biapenem. Panipenem was the most potent against 
penicillin resistant Streptococcus pneumoniae. Biapenem 
was the most potent against A. anitratus. However, 
antimicrobial activities of 4 carbapenems were gener-
ally similar in most bacteria.
Table 1. In vitro antibacterial activities of 4 carbapenems 
Organisms Drugs MIC(mg/L) 
(no. of strains) range MIC50 MIC90 
Methicillin sensitive- Imipenem <0.03 <0.03 <0.03 
Staphylococcus aureus (27) Panipenem <0.03 <0.03 <0.03 
                               Meropenem 0.06-0.12 0.06 0.12
                               Biapenem <0.03-0.12 0.06 0.06
Methicillin resistant- Imipenem <0.03-64 0.12 32 
Staphylococcus aureus (32) Panipenem <0.03-64 0.25 32 
                            Meropenem 0.12-64 2 32
                            Biapenem <0.03-64 1 32
Staphylococcus epidermidis (33) Imipenem <0.03-32 2.0 4.0 
                             Panipenem <0.03-32 0.5 4.0
                               Meropenem 0.06-32 2.0 8.0
                               Biapenem <0.03-32 1.0 8.0
Streptococcus pneumoniae (32) Imipenem <0.03-0.12 <0.03 <0.03 
                             Panipenem <0.03 <0.03 <0.03
                             Meropenem <0.03-0.25 <0.03 <0.03
                             Biapenem <0.03-0.12 <0.03 <0.03
Penicillin Gresistant Imipenem <0.03-0.25 0.12 0.25 
Streptococcus pneumoniae (29) Panipenem <0.03-0.12 0.06 0.06 
                               Meropenem <0.03-0.5 0.25 0.50
                               Biapenem <0.03-0.25 0.12 0.25
Streptococcus pyogenes (32) Imipenem <0.03 <0.03 <0.03 
                            Panipenem <0.03 <0.03 <0.03
                              Meropenem <0.03 <0.03 <0.03
                            Biapenem <0.03 <0.03 <0.03
Enterococcus faecalis (32) Imipenem 0.5-4.0 1.0 2.0 
                                Panipenem 0.5-4.0 1.0 2.0
                                Meropenem 2.0-16 4.0 8.0
                               Biapenem 1.0-16 4.0 8.0
Escherichia coli (32) Imipenem 0.06-0.12 0.06 0.12 
                              Panipenem <0.03-0.12 0.06 0.06
                              Meropenem <0.03-0.06 <0.03 <0.03
                              Biapenem <0.03-0.06 <0.03 0.06 
Klebsiella pneumoniae (32) Imipenem 0.06-0.25 0.12 0.25 
                               Panipenem 0.06-0.5 0.12 0.12
                               Meropenem <0.03 <0.03 <0.03
                              Biapenem <0.03-0.25 0.06 0.25
Proteus vulgaris (28) Imipenem 0.25-8.0 1.0 4.0 
                               Panipenem 0.25-4.0 1.0 4.0
                              Meropenem <0.03-0.5 0.06 0.25
                              Biapenem 0.06-8.0 0.25 4.0
Citrobacterfreundii(28) Imipenem 0.12-1.0 0.25 1.0 
                               Panipenem 0.06-2.0 0.12 0.5
                               Meropenem <0.03-1.0 <0.03 0.12
                              Biapenem <0.03-0.25 0.06 0.25 
Enterobacter cloacae (29) Imipenem 0.12-1.0 0.25 0.25 
                              Panipenem 0.06-0.25 0.12 0.25
                               Meropenem <0.03-1.0 <0.03 0.06
                              Biapenem <0.03-0.25 0.06 0.06
Pseudomonas aeruginosa (31) Imipenem 0.5-64 1.0 8.0 
                               Panipenem 1.0-64 8.0 16 
                               Meropenem 0.25-64 0.5 4.0 
                             Biapenem 0.25-64 0.5 16 
Stenotrophomonas maltophilia Imipenem 4.0-64 >64 >64 
                    (30) Panipenem 8.0-64 >64 >64
                          Meropenem 1.0-64 64 >64
                            Biapenem 4.0-64 >64 >64
Acinetobacter anitratus (30) Imipenem 0.12-0.25 0.12 0.25 
                               Panipenem 0.06-0.25 0.12 0.25
                                Meropenem 0.12-1.0 0.25 1.0 
                              Biapenem 0.06-0.25 0.12 0.12 
Hemophilus influenzae (31) Imipenem 0.06-2.0 0.5 1.0 
                              Panipenem 0.06-2.0 0.25 0.5 
                              Meropenem <0.03-0.25 <0.03 0.06
                               Biapenem <0.03-4.0 0.5 2.0
2.2. The change of susceptibility of clinical isolates to imipenem 
  The in vitro activity of imipenem was compared 
between 1990 and 1992 in Nagasaki University Hospital. 
MIC90s of S. aureus, S. pneumoniae and P. aeruginosa 
increased as shown in Table 2. The resistance rate of 
S. aureus, whose MIC is higher than 25 mg/1, increased 
from 3% to 22%, because the ratio of methicillin resistant 
S. aureus (MRSA) to all S. aureus increased from 27.8% 
(133/478) in 1990 to 65.5% (491/750) in 1992. S. 
pneumoniae, whose MIC is higher than 0.05 mg/l, in-
creased from 9 % to 30% due to the increase of penicillin 
resistant S. pneumoniae. From 14.4% (16/111) in 1990 
to 36.5% (42/115) in 1992. P. aeruginosa, whose MIC 
is higher than 5 mg/1, increased from 20% to 32%. 
However, the susceptibilities of other bacteria such as 
H. influenzae, K. pneumoniae, and M. catarrhalis to 
imipenem did not change. 
  The isolation rates of S. maltophilia from sputum 
increased gradually from 0.9 % in 1984 to 3.5 % in 1991.
2.3. The clinical evaluation of 4 carbapenems in Japan 
a. Clinical review in Nagasaki University 
 The clinical studies performed in our department were 
analyzed including phase II and III trials of 4 carbapenems 
and phase IV trials of imipenem/cilastatin. The clinical 
efficacy rates of imipenem/cilastatin (25 patients with 
respiratory tract infection) and panipenem/beta mipron 
(29 patients with respiratory tract infection) were 79% 
and 77%, and the rates of meropenem (16 patients with 
respiratory tract infection) and biapenem (30 patients 
with respiratory tract infection) were 100% and 96.2%. 
 The comparison between phase II and III (pre-
commercialized), and phase IV trials (post-commercialized) 
of imipenem / cilastatin showed the decreased rates 
from 79% (25 patients) to 67.7% (77 patients). This 
decline of efficacy of imipenem/cilastatin after being 
commercialized was analyzed by investigating the 
underlying diseases and isolated organisms in failure
Table 2. The change of susceptibility to imipenem between 1990 and 1992 
Organisms (no. of strains) Year MIC(mg/L) 
                               range MIC50 MIC90 
Staphylococcus aureus (478) 1990 <0.05->25 <0.05 5.0 
                             1992 <0.05->25 2.5 >25
Streptococcus pneumoniae (111) 1990 <0.05-0.5 <0.05 <0.05 
                              1992 <0.05-0.5 <0.05 0.5 
Enterococcus faecalis (324) 1990 <0.05-25 1.0 2.5 
                              1992 <0.05-5.0 1.0 2.5
Moraxella catarrhalis (36) 1990 <0.05-0.5 <0.05 0.5 
                              1992 <0.05-0.5 <0.05 0.5
Hemophilus influenzae (180) 1990 <0.05-25 0.5 2.5 
                               1992 <0.05-5.0 0.5 1.0 
Escherichia coli (241) 1990 <0.1-1.0 <0.1 <0.1 
                               1992 <0.1-5.0 <0.1 <0.1
Klebsiella pneumoniae (149) 1990 <0.1-5.0 <0.1 1.0 
                               1992 <0.1-5.0 <0.1 1.0
Citrobacterfreundii (34) 1990 <0.1-5.0 1.0 1.0 
                               1992 <0.1-5.0 1.0 1.0
Enterobacter cloacae (189) 1990 <0.1-10 1.0 1.0 
                               1992 <0.1-25 1.0 1.0 
Pseudomonas aeruginosa (695) 1990 <0.1->100 1.0 10 
                           1992 <0.1->100 1.0 25 
Stenotnophomonasmaltophilia(84)1990 1.0->100 >100 >100 
                          1992 1.0->100 >100 >100
Acinetobacter anitratus (119) 1990 <0.1-5.0 0.1 1.0 
                                 1992 <0.1-5.0 0.1 1.0
cases treated by imipenem. P. aeruginosa and S. aureus 
were isolated from 7 and 5 of 22 non-responder failure 
patients in phase TV, respectively, comparing to 2 
P. aeruginosa of 5 failure patients in phase II and III 
trials. The incidence of malignacies in failure cases in-
creased from 4% (1/25) to 23% (18/77) after being 
commercialized. According to these data, imipenem 
was used for the treatment of infection of resistant 
organisms or in immunocompromised patients.
b. Clinical review in Japan 
 The phase II and III trials of carbapenems in internal 
medicine, which were performed separately in Japan, 
were reviewed to evaluate their efficacy and adverse 
reaction. The clinical efficacy rates increased from 73% 
of imipenem/cilastatin to 89.2% of biapenem and adverse 
reaction rates decreased from 4.7 % of imipenem/cilastatin 
to 1.8% of meropenem as drugs developed (Table 3). 
 The clinical efficacies of 4 carbapenems were analyzed 
in the phase II and III trials with respect to the presence 
of underlying diseases and complication. As expected, 
the efficacy rates were lower in patients with underlying 
diseases and complication than those without them. 
Factors of failure in patients treated with carbapenems 
in the phase II and III trials were analyzed Table 4. 
Isolated organisms such as P. aeruginosa and S. aureus
could be the main cause for failure of the therapy. 
P. aeruginosa was isolated at the rate of 64% (50/78) 
in failure patients treated with imipenem / cilastatin, 
67% (28/42) in panipenem/betamipron, 69% (22/32) 
in meropenem, and 60% (9/15) in biapenem. S. aureus 
was isolated at the rate of 8% (6/78) in failure 
patients treated with imipenem/cilastatin, 10% (4/42) 
in panipenem/betamipron, 19% (6/32) in meropenern 
and 13 % (2/15) in biapenem. 
 The clinical efficacies of 4 carbapenems in respiratory 
infection were investigated. The overall efficacy rates 
were 72% in imipenem, 78% in panipenem, 86% in 
meropenem, and 90% in biapenem. The efficacy rates in 
chronic bronchitis, bronchiectasis, pulmonary emphysema, 
and respiratory infection with old pulmonary tuberculosis 
or diabetes mellitus were similar to overall efficacy of 
respiratory infection, however, the efficacy rates in diffuse 
panbronchiolitis and lung cancer were lower than other 
respiratory infection. 
 The clinical efficacies in respiratory infection with 
respect to the isolated organisms were analyzed. However, 
the clinical efficacy against P. aeruginosa respiratory 
infection was improved from 54% in imipenem to 80% 
in biapenem. This could be the main reason for 
improvement of efficacy in overall internal medicine 
department as a whole.
Table 3. Review of 4 carbapenems in phase IT & III in Japan 
       Drug No of Clinical Adverse 
                            patients efficacy rate reaction rate 
Imipenem/Cilastatin 529 73% 4.7% 
Panipenem/betamipron 446 78.9% 3.3% 
Meropenem 567 86.2% 1.8% 
Biapenem 511 89.2% 2.2% 
Table 4. Isolated organisms from failure patients treated with carbapenem 
Organism Imipenem Panipenem Meropenem Biapenem 
Pseudomonas aeruginosa 50(64%) 28(64%) 22(69%) 9(60%) 
Staphylococcus aureus 6(8%) 4(10%) 6(19%) 2(13%) 
Hemophilus influenzae 2(3%) 2(5%) - 2(13%) 
Enterococcus faecalis 3(4%) - 2(6%) 
                 1(7%) 
Enterobacter cloacae 2(3%) - - 1(7%) 
    Others 15(19%) 8(21%) 2(6%) 2(13%) 
    Total 78 42 32 15
 The carbapenems are characterized by having an unsaturated 
bond between C2 and C3 and a carbon atom replacing 
sulphur at position 1 of the thiaaolidine ring. Imipenem is 
combined with cilastatin, an dehydropeptidase inhibitor, 
and panipenem with betarnipron, because imipenem and 
panipenem are not stable to renal dehydropeptidases 
and they are nephrotoxic in certain animals (Kropp et al. 
1982). Meropenem and biapenem are stable to renal 
dehydropeptidases (Edwards et al. 1989; Ubukata et al. 
1990), and they do not require concomitant admini-
stration of an enzyme inhibitor. 
 Figure 1 shows the structure of carbapenem drugs. 
Degradation by hydropeptidase of kidneys causing 
unstability is a disadvantage for imipenem and panipenem. 
On incubation with human renal dehydroxypeptidase I 
(DHP-1) for two hours, degradation of imipenem, 
panipenem and meropenem were 100%, 78% and 48% 
respectively, but about 10% for biapenem. Toxicity to 
central nervous system and kidney are also considerable. 
 Cylastatin sodium, an enzyme inhibitor has been 
combined at 1:1 ratio with imipenem in order to inhibit
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Fig. 1 structure of carbapenems
renal uptake. Panipenem in high dose administration 
causes nephrotoxicity. So, combination with betarnipron 
at 1:1 ratio is done to lower nephrotoxicity. Betarnipron 
has no antimicrobial activity, but improves safety, and 
reduction in nephrotoxicity has been documented. 
Meropenem is stable to enzyme DHP-I, and i s less 
nephrotoxic; thus single drug administration is possible. 
Biapenem is stable for DHP-I, has no toxic effects on 
kidney, so like meropenem single drug administration 
is possible. High toxicity to CNS has been reported 
clinically with earlier carbapenems. In rabbits, no 
abnormality in electroencephalogram and movement 
has been observed with biapenem. The reason was 
thought to be poor penetration through the blood 
brain barrier, and very weak affinity for GABA-
receptor and glycine-receptor has been suggested. 
 Thus newer developments of carbapenems resulted 
in reduction of nephrotoxicity and toxicity to the CNS. 
In addition, single drug administration has been made 
possible. 
 In vitro activity of carbapenems is very potent 
against both gram-positive and gram-negative pathogens 
except S. maltophilia. The highest MICs were obtained 
with S. maltophilia, an MIC50 of > 64 mg/1 being 
demonstrated for all compounds tested. This may explain 
the gradual increase of isolation rates from sputum in 
Nagasaki University Hospital. Some strains of MRSA, 
S. epidermidis, E. faecalis and P. aeruginosa are not 
sensitive to carbapenems. All carbapenems were very 
active against the bacteria tested, however, MIC90s were 
slightly affected by the penicillin-resistant strains. No 
Enterobacteriaceae were resistant to carbapenems and 
meropenem was the most potent to most of the tested 
Enterobacteriaceae. Meropenem is reported to be more 
active than imipenem against most of the members of 
the family Enterobacteriaceae, but less active against 
gram-positive aerobic species (Edwards et al. 1989). 
This tendency is also true in the relationship between 
biapenem and imipenem (Yoshida & Mitsuhashi 1990; Neu 
et al. 1992; Catchpole et al. 1992; Malanoski et al. 1993). 
Sader & Jones (1993) reported that imipenem, meropenem 
and biapenem are potent to Enterobacteriaceae, P. 
aeruginosa and Bacteroides fragilis but not active against 
S. maltophilia, oxacillin-resistant Staphylococcus spp. and 
Enterococcus spp. 
  The rapid increase of resistant strains of S. aureus, 
S. pneumoniae and P. aeruginosa to imipenem is a problem 
in Nagasaki University Hospital. MRSA increased from 
27.8% in 1990 to 65.6% in 1992, and penicillin-resistant 
S. pneumoniae from 14.4% in 1990 to 36.5% in 1992. 
This plays an important role of decreased clinical effi-
cacy of imipenem in Nagasaki University Hospital 
after being commercialized.
 Clinical efficacies of four carbapenems in phase II & III 
trials in Japan were reanalyzed. Biapenem demonstrated 
the highest efficacy rate and meropenem 'showed the 
lowest rate of adverse reaction among four carbapenems 
(Shinyaku Symposium 1984; Shinyaku Symposium 1990; 
Shinyaku Symposium 1991; Shinyaku Symposium 1993). 
Isolated organisms were also analyzed in failure patients 
treated with these carbapenems, and P. aeruginosa and 
S. aureus were the major isolates. 
 Double blind comparative studies between imipenem 
and other 3 carbapenems were performed in Japan. 
The comparative studies for pneumonia among three 
groups; between panipenem/betamipron (1g/day) and 
imipenem/cilastatin (1g/day), meropenem (0.5g/day) and 
imipenem/cilastatin (1g/day) and biapenem (600mg/day) 
and imipenem/cilastatin (1000mg/day), as phase III trials 
performed in Japan, revealed no significant difference 
between imipenem and other carbapenems, however, 
only biapenem showed better clinical efficacy rate 
(94.8%) than imipenem/cilastatin (92.8%) (Hara et al. 
1992; Hara et al. 1992; Matsumoto et al. 1995). 
 Most carbapenems have been developed in Japan, 
and they are regarded to be an all-mighty antibiotic 
due to their potent antimicrobial activity and wide 
spectrum. However, the present study suggested that 
administration of carbapenems to patients with severe 
underlying disease or infection caused by less sensitive 
organisms such as P. aeruginosa and MRSA may reduce 
its value for one of the best antibiotics.
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